61 NORTH BEACON STREET, BOSTON, MA
Annual Report to Security Holders
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Enters Underwriting Agreement for 45.86M Shares
Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Changes in Board, Management or Compensation
Announces Closing of Upsized $85 Million Private Placement
Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
News, Legal Opinion, Material Contracts
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence